US3714344A - Method for determining thyroxine in blood serum and reagent therefor - Google Patents

Method for determining thyroxine in blood serum and reagent therefor Download PDF

Info

Publication number
US3714344A
US3714344A US00865785A US3714344DA US3714344A US 3714344 A US3714344 A US 3714344A US 00865785 A US00865785 A US 00865785A US 3714344D A US3714344D A US 3714344DA US 3714344 A US3714344 A US 3714344A
Authority
US
United States
Prior art keywords
thyroxine
blood serum
radioactive
solution
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00865785A
Inventor
J Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Mallinckrodt Chemical Works
Original Assignee
Mallinckrodt Chemical Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Chemical Works filed Critical Mallinckrodt Chemical Works
Application granted granted Critical
Publication of US3714344A publication Critical patent/US3714344A/en
Assigned to MALLINCKRODT, INC. reassignment MALLINCKRODT, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: MALCO, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G21NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21HOBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
    • G21H5/00Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for 
    • G21H5/02Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for  as tracers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/825Pretreatment for removal of interfering factors from sample
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/826Additives, e.g. buffers, diluents, preservatives

Definitions

  • T-4 The serum protein, thyroxine-binding globulin
  • T-4 radioactive T-4, that is T-4 containing radioactive iodine such as iodine-125, is added to a solution containing barbital buffered TBG, essentially all of the T-4 will be bound to the TBG.
  • the radioactive T-4 will be displaced from the TBG in proportion to the amount of stable T-4 that is added. If another T-4 binding agent, such as an ion-exchange resin, is now added to this system, it will bind the radioactive T-4 that has been displaced from the TBG.
  • another T-4 binding agent such as an ion-exchange resin
  • the degree of radioactive T-4 displacement and hence the amount of stable thyroxine added to the TBG can be determined by removing the ion-exchange resin from the system and comparing the radioactivity now emitted by the TBG solution with its original radioactivity.
  • the radioactivity of the TBG solution decreases with each successive increase in added stable T-4.
  • diluted blood serum is customarily used as the source of TBG. It has not been the practice to subject it to any further treatment.
  • the serum T-4 In order to determine T-4 in blood serum, the serum T-4 must first be separated from the binding proteins. This is accomplished by denaturing the proteins with alcohol. The denatured proteins release most (approximately 80 percent) of their bound T-4 which is removed in the alcoholic supernatant after centrifugation.
  • this alcoholic extract is evaporated to avoid possible errors introduced by alcohol in the test mixture. Generally, 30 to 120 minutes are required to complete this step, depending upon the number of samples tested.
  • the present invention is thus directed to the method of determining the thyroxine content of blood serum using radioactive thyroxine as a tracer compound which comprises the steps of adding to a known quantity of a reagent consisting essentially of a solution containing thyroxine-binding globulin and radioactive thyroxine, an alcoholic extract of a sample of blood serum whose thyroxine content is to be determined and an ion-exchange resin, maintaining the globulin solution in contact with the resin for a predetermined BRIEF DESCRIPTION OF THE DRAWING
  • FIG. 1 is agraph depicting an illustrative standard curve obtained by plotting the radioactivity of treated thyroxine-binding globulin samples against amounts of stable thyroxine.
  • control samples are prepared.
  • 0.3 ml. of an ethanolic solution containing a known amount (e.g., 0, and i2 nanograms) of stable thyroxine are added.
  • a strip of ion-exchange resin membrane is then added to each test vial.
  • the'ion-exchange resin may be either anion-selective or cation-selective; Many such resins are available in the form of membranes.
  • a commercially available anion-selective resin suitable for the purposes of thisinvention is designated AR-ill (manufactured by Ionics Incorporated, -Watertown, Massachusetts).
  • the resin uptake of radioactive thyroxine is a function of rotation time, it is essential that the rotation time be the same for both the unknown and control samples.
  • the resin strip is removed with a forceps and discarded.
  • the radioactivity of each vial is then counted and recorded as the post-count. A minimum of 10,000 counts per minute will insure an error of less than 2 percent.
  • the pre-count is also advantageously determined by counting an unused vial containing the TBG-radioactive T-4 solution. The precount/post-count ratio is calculated for each of the samples.
  • the values for the standard samples are then plotted against the amount of added T-4, a straight line is drawn through the points, and the thyroxine content of the unknown serum samples is read from the resulting graph (see FIG. 1). Since the alcohol extracts approximately 80 percent of the T4 from the serum, the value read from the graph should be divided by the extraction efficiency (approximately 0.8) to give the actual thyroxine content of the serum.
  • This corrected value then represents the amount of T-4 (nanograms) in each 0.1 ml. of serum which is numerically equivalent to the number of ugm. of T-4 per 100 ml. (ugm. of patient serum.
  • the special TBG solution is conveniently prepared by passing the blood serum through a column containing a suitable anion-exchange resin which is capable of adsorbing the thyroxine but not the serum protein.
  • a suitable procedure for preparing the special TBG solution is as follows. To 137 m1. of serum is added 3280 ml. of a pH 8.6 barbital buffer solution containing 0.64 percent sodium chloride, 0.23 percent barbital sodium, and 0.6 percent barbital. A small amount of radioactive thyroxine (approximately 0.24 millicuries) is also added to serve as a tracer for determining the efficiency of the extraction.
  • An extraction column for this purpose is prepared by adding a sufficient amount of resin to a suitable glass column to provide a bed volume of 1,200 ml. and a flow rate of approximately 25 ml. per minute.
  • a strongly basic quaternary ammonium type resin is suitable.
  • a commercially available resin of this kind designated IRA-400 manufactured by the Rohm and Haas Company
  • IRA-400 is satisfactory, but other anion-selective or cation-selective resins may be used instead.
  • the resin is added to the column as a water slurry and a layer of water is always maintained above the resin.
  • the column is connected to a reservoir containing the serum solution to be extracted, and flow of the serum through the column is begun. Periodically a 1 ml. sample of the eluate is removed and its radioactivity counted to measure the efficiency of the extraction.
  • the radioactivity of the eluate should be percent or less that of the stock solution.
  • the extracted serum solution is then preferably passed through a 0.22 micron filter. More (approximately 0.30 millicuries) radioactive thyroxine is then added to the eluate and the latter is diluted with six times its volume of the aforementioned buffer solution.
  • the resulting solution should have a pH of 8.6.
  • a useful kit consists of a number of 4 ml. test vials made of glass and provided with screw caps.
  • the vials should include 4 cc. of the above TBG solution and should be matched for radioactivity.
  • the standard samples should contain known amounts of stable thyroxine (e.g., 0 and 12 nanograms) in 0.3 ml. of alcohol.
  • a container of alcohol from the same source used to prepare the control samples should also be supplied.
  • the kit should also include the required ionexchange resin, the latter preferably being in the form of membrane strips.
  • the other necessary equipment such as syringes, radiation counter and rotator are standard laboratory equipment.
  • the method for determining the thyroxine content of blood serum using radioactive thyroxine as a tracer compound which comprises the steps of adding to a known quantity of a reagent consisting essentially of a solution containing thyroxine-binding globulin and radioactive thyroxine,
  • said reagent comprises a buffered solution of radioactive thyroxine and blood serum from which most of the naturally occurring thyroxine has been extracted.
  • the method for preparing a reagent for use in determining the thyroxine content of blood serum which comprises passing diluted blood serum through a column containing an ion-exchange resin to extract most of the naturally occurring thyroxine from the serum, and adding radioactive thyroxine to the resulting eluate.
  • a reagent for use in determining the thyroxine content of blood serum which comprises a buffered solution of radioactive thyroxine and blood serum from amount of thyroxine-l l 25 to act as a tracer, two control samples containing a known amount of thyroxine dissolved in a predetermined volume of alcohol, a quantity of alcohol from the same source used to prepare the control sample, and a plurality of resin membrane strips whose dimensions permit them to fit loosely in the test containers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

An improved method for determining the thyroxine content of blood serum with the aid of a radioactive thyroxine tracer employs a reagent consisting of blood serum from which most of the naturally occurring thyroxine has been removed, for example by passing the serum through an ion-exchange column. Also, by comparing the radioactivity of an unknown sample with reference standards containing the same amount of alcohol from the same source, the usual and time-consuming alcohol evaporation step is eliminated.

Description

Waited States Patent 1 1 Brown 1451 Jan. 30, 1973 [54] METHOD FOR DETERMINING Primary Examiner-Benjamin R. Padgett THYROXINE IN BLOOD SERUM AND Attorney-Koenig, Senniger, Powers & Leavitt REAGENT THEREFOR [75] Inventor: James L. Brown, St. Louis, Mo.
[73] Assignee: Mallinckrodt Chemical Works, St. [57] ABSTRACT Louis, Mo. An improved method for determining the thyroxine [22] Flled' 1969 content of blood serum with the aid of a radioactive [21] Appl. No.: 865,785 thyroxine tracer employs a reagent consisting of blood serum from which most of the naturally occurring 52 us. (:1. ..424/1 23/230 B 252/3011 R thymine has emm!"e by passir'g 51 Int. c1. .:..A6lk 27/04 the Serum thmugh ion-exchange coiumn- Also, by [58] Field of Search ..424 1;23/230 11,230 B; comparing the radioactivity of an unknown Sample 252/301.l R, 301.] S; 250/106 T with reference standards containing the same amount of alcohol from the same source, the usual and time- [56] References Cited consuming alcohol evaporation step is eliminated.
UNITED STATES PATENTS 9 Claims, 1 Drawing Figure 3,414,383 12/1968 Murphy ..23/230 B PATENTEDJMQQ m3 3,714,344
STANDARD CURV E PRE- COUNT/POSTCOUNT O I I l NANOGRAMS (n OF T-4 METHOD FOR DETERMINING TIIYROXINE IN BLOOD SERUM AND REAGENT THEREFOR BACKGROUND OF THE INVENTION The serum protein, thyroxine-binding globulin (TBG) has a relatively high and specific affinity for binding the thyroid hormone substance thyroxine (hereinafter referred to as "T-4"). It is also known that if radioactive T-4, that is T-4 containing radioactive iodine such as iodine-125, is added to a solution containing barbital buffered TBG, essentially all of the T-4 will be bound to the TBG. If stable T-4 is then added to the TBG solution, the radioactive T-4 will be displaced from the TBG in proportion to the amount of stable T-4 that is added. If another T-4 binding agent, such as an ion-exchange resin, is now added to this system, it will bind the radioactive T-4 that has been displaced from the TBG.
Various techniques based on the above principles have been devised. A particularly convenient method employing ion-exchange resin membranes to adsorb the displaced radioactive T-4 is disclosed in the copending application of Ella M. Bettinger and James L. Brown, Ser. No. 821,097,filed May 1, 1969.
The degree of radioactive T-4 displacement and hence the amount of stable thyroxine added to the TBG can be determined by removing the ion-exchange resin from the system and comparing the radioactivity now emitted by the TBG solution with its original radioactivity. When increasing amounts of stable T-4 are added to solutions containing the same amounts of radioactive T-4 and TBG and treated as above, the radioactivity of the TBG solution decreases with each successive increase in added stable T-4. By plotting the radioactivity of the treated sample against the amount of stable T-4, a graph is obtained like that shown in FIG. 1. If unknown amounts of T-4 are added to the TBG solution and treated in an identical manner, the amount of T-4 thus added can be read from the graph.
For this determination, diluted blood serum is customarily used as the source of TBG. It has not been the practice to subject it to any further treatment.
In order to determine T-4 in blood serum, the serum T-4 must first be separated from the binding proteins. This is accomplished by denaturing the proteins with alcohol. The denatured proteins release most (approximately 80 percent) of their bound T-4 which is removed in the alcoholic supernatant after centrifugation.
In methods known heretofore, this alcoholic extract is evaporated to avoid possible errors introduced by alcohol in the test mixture. Generally, 30 to 120 minutes are required to complete this step, depending upon the number of samples tested.
SUMMARY OF THE INVENTION Among the several objects of the invention may be noted the provision of an improved method for determining the thyroxine content of blood serum; the provision of such a method which requires substantially less time than methods used heretofore; the provision of a special thyroxine-binding globulin reagent whichimproves the accuracy of the method of the invention; and the provision of a kit which facilitates the practice of the method of the invention. Other objects and features will be in part apparent and in part pointed out hereinafter.
The present invention is thus directed to the method of determining the thyroxine content of blood serum using radioactive thyroxine as a tracer compound which comprises the steps of adding to a known quantity of a reagent consisting essentially of a solution containing thyroxine-binding globulin and radioactive thyroxine, an alcoholic extract of a sample of blood serum whose thyroxine content is to be determined and an ion-exchange resin, maintaining the globulin solution in contact with the resin for a predetermined BRIEF DESCRIPTION OF THE DRAWING FIG. 1 is agraph depicting an illustrative standard curve obtained by plotting the radioactivity of treated thyroxine-binding globulin samples against amounts of stable thyroxine.
DESCRIPTION OF THE PREFERRED EMBODIMENTS Using the method of the present invention, the time requiredto determine thyroxine in blood serum is substantially shortened since evaporation of the alcoholic extract is unnecessary. Moreover, using the special TBG reagent disclosed herein, the accuracy of the method is substantially improved because the slope of the lineshown in FIG. 1 is steeper-than that obtained with untreated diluteTBG reagent under the same con ditions. g
' The following example illustrates the practice of the invention:
For example, about 10 ml. of blood whose thyroxine is to be determined is withdrawn and allowed to coagulate. The serum is removed and 1 ml. is added dropwise to 2 ml. of percent ethanol in a centrifuge tube'and the contents are well mixed to denature the serum proteins. This alcoholic mixture is then centrifuged at 2,500 rpm for 4-5 minutes and 0.3 ml. of the supernatant liquid is withdrawn and transferred to a suitable test vialwhich'contains 4 ml. of thespecial TBG solution whose preparation is described hereinafter.
In the same manner, several control samples are prepared. In place of the ethanolic serum extract, 0.3 ml. of an ethanolic solution containing a known amount (e.g., 0, and i2 nanograms) of stable thyroxine are added.
A strip of ion-exchange resin membrane is then added to each test vial. Since thyroxine is amphoteric, the'ion-exchange resin may be either anion-selective or cation-selective; Many such resins are available in the form of membranes. For example; a commercially available anion-selective resin suitable for the purposes of thisinvention is designated AR-ill (manufactured by Ionics Incorporated, -Watertown, Massachusetts).
After the resin strips are added, the vials are capped and rotated for exactly 1 hour at room temperature. It
is convenient to use one of the commercial rotators especially designed for this purpose. Since the resin uptake of radioactive thyroxine is a function of rotation time, it is essential that the rotation time be the same for both the unknown and control samples. At the end of the 1 hour rotation time, the resin strip is removed with a forceps and discarded. The radioactivity of each vial is then counted and recorded as the post-count. A minimum of 10,000 counts per minute will insure an error of less than 2 percent. The pre-count is also advantageously determined by counting an unused vial containing the TBG-radioactive T-4 solution. The precount/post-count ratio is calculated for each of the samples. The values for the standard samples are then plotted against the amount of added T-4, a straight line is drawn through the points, and the thyroxine content of the unknown serum samples is read from the resulting graph (see FIG. 1). Since the alcohol extracts approximately 80 percent of the T4 from the serum, the value read from the graph should be divided by the extraction efficiency (approximately 0.8) to give the actual thyroxine content of the serum. This corrected value then represents the amount of T-4 (nanograms) in each 0.1 ml. of serum which is numerically equivalent to the number of ugm. of T-4 per 100 ml. (ugm. of patient serum.
The special TBG solution is conveniently prepared by passing the blood serum through a column containing a suitable anion-exchange resin which is capable of adsorbing the thyroxine but not the serum protein.
A suitable procedure for preparing the special TBG solution is as follows. To 137 m1. of serum is added 3280 ml. of a pH 8.6 barbital buffer solution containing 0.64 percent sodium chloride, 0.23 percent barbital sodium, and 0.6 percent barbital. A small amount of radioactive thyroxine (approximately 0.24 millicuries) is also added to serve as a tracer for determining the efficiency of the extraction.
An extraction column for this purpose is prepared by adding a sufficient amount of resin to a suitable glass column to provide a bed volume of 1,200 ml. and a flow rate of approximately 25 ml. per minute. For this purpose, a strongly basic quaternary ammonium type resin is suitable. For example, a commercially available resin of this kind designated IRA-400 (manufactured by the Rohm and Haas Company) is satisfactory, but other anion-selective or cation-selective resins may be used instead.
The resin is added to the column as a water slurry and a layer of water is always maintained above the resin. The column is connected to a reservoir containing the serum solution to be extracted, and flow of the serum through the column is begun. Periodically a 1 ml. sample of the eluate is removed and its radioactivity counted to measure the efficiency of the extraction.
The radioactivity of the eluate should be percent or less that of the stock solution. The extracted serum solution is then preferably passed through a 0.22 micron filter. More (approximately 0.30 millicuries) radioactive thyroxine is then added to the eluate and the latter is diluted with six times its volume of the aforementioned buffer solution. The resulting solution should have a pH of 8.6.
The usefulness and accuracy of the method is increased if the analyst is provided with a kit containing all the special reagents and other supplies required. For example, a useful kit consists of a number of 4 ml. test vials made of glass and provided with screw caps. The vials should include 4 cc. of the above TBG solution and should be matched for radioactivity. The standard samples should contain known amounts of stable thyroxine (e.g., 0 and 12 nanograms) in 0.3 ml. of alcohol. A container of alcohol from the same source used to prepare the control samples should also be supplied. The kit should also include the required ionexchange resin, the latter preferably being in the form of membrane strips. The other necessary equipment such as syringes, radiation counter and rotator are standard laboratory equipment.
In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous results attained.
As many changes could be made in the above methods and products without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.
What is claimed is:
1. The method for determining the thyroxine content of blood serum using radioactive thyroxine as a tracer compound which comprises the steps of adding to a known quantity of a reagent consisting essentially of a solution containing thyroxine-binding globulin and radioactive thyroxine,
a. an alcoholic extract of a sample of blood serum whose thyroxine content is to be determined, and
b. an ion-exchange resin,
maintaining the said globulin solution in contact with the said resin for a predetermined length of time;
separating the ion-exchange resin from the globulin solution; and
comparing the radioactivity of the globulin solution with that of globulin solutions to which have been added known amounts of stable thyroxine dissolved in the same volume of alcohol from the same source as that present in said alcoholic serum extract.
2. The method according to claim 1 wherein said reagent comprises a buffered solution of radioactive thyroxine and blood serum from which most of the naturally occurring thyroxine has been extracted.
3. The method according to claim 1 wherein the radioactive thyroxine is iodine-125.
4. The method according to claim 1 wherein the globulin solution is maintained in contact with the resin by rotating a sealed vessel containing said solution and resin.
5. The method according to claim 1 wherein said ionexchange resin is in the form of a membrane strip.
6. The method for preparing a reagent for use in determining the thyroxine content of blood serum which comprises passing diluted blood serum through a column containing an ion-exchange resin to extract most of the naturally occurring thyroxine from the serum, and adding radioactive thyroxine to the resulting eluate.
7. A reagent for use in determining the thyroxine content of blood serum which comprises a buffered solution of radioactive thyroxine and blood serum from amount of thyroxine-l l 25 to act as a tracer, two control samples containing a known amount of thyroxine dissolved in a predetermined volume of alcohol, a quantity of alcohol from the same source used to prepare the control sample, and a plurality of resin membrane strips whose dimensions permit them to fit loosely in the test containers.

Claims (8)

1. The method for determining the thyroxine content of blood serum using radioactive thyroxine as a tracer compound which comprises the steps of adding to a known quantity of a reagent consisting essentially of a solution containing thyroxine-binding globulin and radioactive thyroxine, a. an alcoholic extract of a sample of blood serum whose thyroxine content is to be determined, and b. an ion-exchange resin, maintaining the said globulin solution in contact with the said resin for a predetermined length of time; separating the ion-exchange resin from the globulin solution; and comparing the radioactivity of the globulin solution with that of globulin solutions to which have been added known amounts of stable thyroxine dissolved in the same volume of alcohol from the same source as that present in said alcoholic serum extract.
2. The method according to claim 1 wherein said reagent comprises a buffered solution of radioactive thyroxine and blood serum from which most of the naturally occurring thyroxine has been extracted.
3. The method according to claim 1 wherein the radioactive thyroxine is iodine-125.
4. The method according to claim 1 wherein the globulin solution is maintained in contact with the resin by rotating a sealed vessel containing said solution and resin.
5. The method according to claim 1 wherein said ion-exchange resin is in the form of a membrane strip.
6. The method for preparing a reagent for use in determining the thyroxine content of blood serum which comprises passing diluted blood serum through a column containing an ion-exchange resin to extract most of the naturally occurring thyroxine from the serum, and adding radioactive thyroxine to the resulting eluate.
7. A reagent for use in determining the thyroxine content of blood serum which comprises a buffered solution of radioactive thyroxine and blood serum from which most of the naturally occurring thyroxine has been extracted.
8. A reagent according to claim 7 wherein the radioactive thyroxine contains iodine-125.
US00865785A 1969-05-01 1969-10-13 Method for determining thyroxine in blood serum and reagent therefor Expired - Lifetime US3714344A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82109769A 1969-05-01 1969-05-01
US86578569A 1969-10-13 1969-10-13

Publications (1)

Publication Number Publication Date
US3714344A true US3714344A (en) 1973-01-30

Family

ID=27124511

Family Applications (1)

Application Number Title Priority Date Filing Date
US00865785A Expired - Lifetime US3714344A (en) 1969-05-01 1969-10-13 Method for determining thyroxine in blood serum and reagent therefor

Country Status (11)

Country Link
US (1) US3714344A (en)
JP (2) JPS5617620B1 (en)
BE (1) BE749772A (en)
CH (1) CH526781A (en)
DE (1) DE2021968A1 (en)
FR (1) FR2047211A5 (en)
GB (1) GB1314263A (en)
IL (1) IL34387A (en)
IT (1) IT943545B (en)
NL (2) NL7006455A (en)
SE (1) SE378679B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911096A (en) * 1972-06-23 1975-10-07 Professional Staff Ass Of The Radioimmunoassay for measurement of thyroxine (T{HD 4{B ) and triiodothyonine (T{HD 3{B ) in blood serum
US3929981A (en) * 1974-02-27 1975-12-30 Squibb & Sons Inc Method for determining thyroid function
US3947564A (en) * 1973-05-29 1976-03-30 Bio-Rad Laboratories Radioactive determination of serum thyroxine
US3966897A (en) * 1973-04-02 1976-06-29 Marine Colloids, Inc. Medium for use in bioassay and method of using same
US4282002A (en) * 1979-09-06 1981-08-04 Akzona Incorporated Sensitized sheep stroma immunoassay for rheumatoid factor
USRE32098E (en) * 1972-06-23 1986-03-25 Research And Education Institute, Inc. Radioimmunoassay for measurement of thyroxine (T4) and triiodothyronine (T3) in blood serum
US5359093A (en) * 1992-03-30 1994-10-25 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US5593896A (en) * 1992-03-30 1997-01-14 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US6242261B1 (en) 1992-02-10 2001-06-05 University Of Saskatchewan Assessment of ion availability in heterogeneous media using ion-exchange membranes
US20080020486A1 (en) * 2004-11-25 2008-01-24 Veolia Eau - Compagnie Generale Des Eaux Case For Sampling Water And Capturing Substances That Generate Orders And/Or Tastes Present In Water

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605447A (en) * 1975-06-26 1976-12-28 Byk Mallinckrodt Chem Prod RADIOIMMUNO TEST METHOD FOR THE DETERMINATION OF THYROXIN.
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
US11768689B2 (en) 2013-08-08 2023-09-26 Movidius Limited Apparatus, systems, and methods for low power computational imaging

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3414383A (en) * 1965-08-09 1968-12-03 Canadian Patents Dev Determination of thyroxine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3414383A (en) * 1965-08-09 1968-12-03 Canadian Patents Dev Determination of thyroxine

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911096A (en) * 1972-06-23 1975-10-07 Professional Staff Ass Of The Radioimmunoassay for measurement of thyroxine (T{HD 4{B ) and triiodothyonine (T{HD 3{B ) in blood serum
USRE32098E (en) * 1972-06-23 1986-03-25 Research And Education Institute, Inc. Radioimmunoassay for measurement of thyroxine (T4) and triiodothyronine (T3) in blood serum
US3966897A (en) * 1973-04-02 1976-06-29 Marine Colloids, Inc. Medium for use in bioassay and method of using same
US3947564A (en) * 1973-05-29 1976-03-30 Bio-Rad Laboratories Radioactive determination of serum thyroxine
US3929981A (en) * 1974-02-27 1975-12-30 Squibb & Sons Inc Method for determining thyroid function
US4282002A (en) * 1979-09-06 1981-08-04 Akzona Incorporated Sensitized sheep stroma immunoassay for rheumatoid factor
US6242261B1 (en) 1992-02-10 2001-06-05 University Of Saskatchewan Assessment of ion availability in heterogeneous media using ion-exchange membranes
US5359093A (en) * 1992-03-30 1994-10-25 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US5593896A (en) * 1992-03-30 1997-01-14 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US20080020486A1 (en) * 2004-11-25 2008-01-24 Veolia Eau - Compagnie Generale Des Eaux Case For Sampling Water And Capturing Substances That Generate Orders And/Or Tastes Present In Water

Also Published As

Publication number Publication date
SE378679B (en) 1975-09-08
IL34387A0 (en) 1970-06-17
JPS5542704B1 (en) 1980-11-01
IT943545B (en) 1973-04-10
CH526781A (en) 1972-08-15
GB1314263A (en) 1973-04-18
FR2047211A5 (en) 1971-03-12
IL34387A (en) 1973-04-30
JPS5617620B1 (en) 1981-04-23
NL7417037A (en) 1975-04-29
DE2021968A1 (en) 1970-11-05
BE749772A (en) 1970-10-30
NL7006455A (en) 1970-11-03

Similar Documents

Publication Publication Date Title
Benson Jr et al. Accelerated chromatographic analysis of amino acids in physiological fluids containing glutamine and asparagine
Murphy The determination of thyroxine by competitive protein-binding analysis employing an anion-exchange resin and radiothyroxine
US3714344A (en) Method for determining thyroxine in blood serum and reagent therefor
Nauman et al. Total and free triiodothyronine in human serum
LEE et al. Determination of the free thyroxine content of serum
GOETZ et al. A simple immunoassay for insulin: application to human and dog plasma
US3776698A (en) Test for thyroid hormone
Seligson et al. Measurement of thyroxine by competitive protein binding
Turnell et al. Automated sequential process for preparing samples for analysis by high-performance liquid chromatography
US3659104A (en) Method of measuring serum thyroxine
Belisle et al. Method for the determination of the total fluorine content of whole blood, serum/plasma, and other biological samples
CA1040079A (en) Radioassay of vitamin b-12
US4810391A (en) Separation of hemoglobin A2 from hemoglobin mixture
SU576976A3 (en) Method of determining effective thyroxin ratio in blood sample
US3745211A (en) Method for determining thyroxine in blood serum and reagent therefor
Thrivikraman et al. Liquid chromatographic analysis of nanogram quantities of ascorbate in brain tissue
Hamaji et al. Estimation of catecholamines in human plasma by ion-exchange chromatography coupled with fluorimetry
Strelow Separation of thorium from rare earths, zirconium, and other elements by cation exchange chromatography
IE46765B1 (en) Method for determination of free hormones in biological fluids
Veillon et al. Measurement of blood volume with an enriched stable isotope of chromium (53Cr) and isotope dilution by combined gas chromatography-mass spectrometry
Klein et al. An ultrasensitive assay for soluble sulfhydryl and its application to the study of glutathione levels during the HeLa life cycle
Long et al. A rapid ion exchange method for quantitation of the urinary excretion of 3-methylhistidine
US3929981A (en) Method for determining thyroid function
Mechanic An automated scintillation counting system with high efficiency for continuous analysis: Cross-links of [3H] NaBH4-reduced collagen
Shefner et al. A tracer method for the determination of microgram quantities of protein

Legal Events

Date Code Title Description
AS Assignment

Owner name: MALLINCKRODT, INC.

Free format text: CHANGE OF NAME;ASSIGNOR:MALCO, INC.;REEL/FRAME:004572/0403

Effective date: 19860101